Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab

URN to cite this document:: urn:nbn:de:bvb:355-epub-528179
DOI to cite this document:: 10.5283/epub.52817

Magnus, Clara Luzia ; Hiergeist, Andreas ; Schuster, Philipp ; Rohrhofer, Anette ; Medenbach, Jan

; Gessner, André ; Peterhoff, David

; Schmidt, Barbara

License: Creative Commons Attribution 4.0
PDF - Published Version
(2MB)

Date of publication of this fulltext: 09 Sep 2022 13:06

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain with angiotensin-converting enzyme 2 (ACE2), while class 3 antibodies target a highly conserved epitope outside the ACE2 binding site. We aimed to investigate the plasticity of the spike protein by propagating wild-type SARS-CoV-2 in the presence of class 3 antibody S309. ...